With our panel of diverse thought leaders we will strategically explore the following questions:

• What is the unmet need in NASH?
• How is the treatment landscape evolving and what does the future of NASH hold?
• Why is NASH of such high interest to the pharma/biotech space?
• What are the implications to the healthcare system if new NASH therapies are approved? – Who will treat? Who will be treated? Who will pay?
• What does a pharma company need to do to shape the market and achieve a lasting impact in the space?
• What are the pricing analogies (e.g. Sovaldi) that might help prepare a biopharma company for successful commercialization?

Speakers:

• Jagpreet Chhatwal, PhD, Assistant Professor, Harvard Medical School, Senior Scientist, MGH Institute for Technology Assessment
• Rosana Kapeller, MD, PhD, Chief Scientific Officer, Nimbus Therapeutics
• Raza Malik, MD, PhD, FRCP, Medical Director, Hepatology & Hepatobiliary Program, Beth Israel Deaconess Medical Center, Harvard Medical School

Moderator:

• Amama Sadiq, MD, MPH, Medical Director, Clarion Healthcare